On This Day in Health: January 14, 1898
On January 14, 1898, the pharmaceutical company Bayer filed and secured the trademark for “Aspirin,” a watershed moment in the history of medicine. While acetylsalicylic acid—the active ingredient in aspirin—had already been synthesized in 1897 by Bayer chemist Felix Hoffmann, the trademark registration transformed it from a promising laboratory compound into a branded product sold worldwide. Before aspirin, painkillers such as salicylic acid were common treatments for fever and inflammation, but they often caused severe side effects. Aspirin’s development offered a formulation that was more tolerable for many patients, and its arrival accelerated the shift toward standardized, industrially produced medicines.
Aspirin quickly gained recognition not only as a pain reliever, but also as one of the first mass-market drugs whose safety, quality, and dosing could be controlled at a large scale. The product’s launch coincided with a period of rapid growth in pharmaceutical science, when companies began to treat drug development as a systematic research discipline rather than solely an artisanal chemical craft. Doctors soon prescribed aspirin to treat headaches, rheumatic pain, and fever, and it became a staple in medical kits across Europe and the United States. By the early 20th century, aspirin was widely hailed as a breakthrough drug, and demand soared as global manufacturing expanded.
Aspirin’s story also became intertwined with world events. During World War I, Bayer lost the trademark rights in several countries as part of war reparations and international patent restrictions. As a result, “aspirin” gradually shifted from a protected brand name to a generic term in much of the world. Despite these legal and commercial changes, the legacy of January 14, 1898 continued. The name registration marked the beginning of one of the most successful and enduring medications ever developed. Aspirin would eventually be recognized not only as a painkiller, but also as a treatment to reduce the risk of blood clots and heart attack—a discovery that reshaped its role in preventive medicine decades later.
The registration of Aspirin stands as a milestone in the transition to modern pharmaceuticals: a moment when chemistry, regulation, branding, and clinical practice converged to create a product used in virtually every corner of the world. More than a century later, aspirin remains one of the most widely used medications, its origins rooted in that turning point on January 14, 1898.
By January 14, 1898, modern pharmaceutical science was beginning to take shape. Chemists were moving beyond traditional remedies like willow bark and salicylic acid, which were known to relieve pain and fever but often caused significant stomach irritation. At Bayer in Germany, chemist Felix Hoffmann had recently synthesized a more stable and tolerable compound: acetylsalicylic acid.
On this day, Bayer formally registered the trademark “Aspirin,” turning a promising laboratory compound into a branded medicine. The decision reflected a growing trend in health care: standardizing drugs so that their quality, dosage, and identity were consistent, and linking them to a recognizable name that physicians and patients could request with confidence.
In the years following the 1898 trademark registration, Aspirin quickly spread through medical practice. Physicians prescribed it for headaches, rheumatic pain, and fevers, and many patients found it more tolerable than earlier salicylate-based medicines. Packaged in standardized doses, it was easier for doctors to recommend and for pharmacists to dispense.
Still, its early use had limitations. The drug was not a cure for underlying diseases, and its side effects—especially at higher doses—were not fully understood. Access was uneven, too, as early supplies were concentrated in Europe and wealthier urban centers. Even so, Aspirin’s arrival marked a practical shift toward mass-produced, research-based medicines that could be prescribed and trusted across national borders.
Over the 20th century, Aspirin evolved from a pain reliever into a cornerstone of cardiovascular care. Research showed that low doses could help reduce the risk of blood clots, heart attacks, and certain types of stroke in select patients. This expanded role made the drug a central part of preventive strategies in cardiology, even as guidelines continued to be refined in light of bleeding risks.
The story of Aspirin also illustrates broader changes in health and regulation. During and after World War I, Bayer lost its exclusive rights to the name in many countries, and “aspirin” became a generic term. The drug’s widespread use influenced how regulators evaluated safety, labeling, and marketing of over-the-counter medicines. From that first trademark filing on January 14, 1898, Aspirin helped define what a modern, globally recognized medication could look like—and how it could shape everyday health decisions for generations.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.